

Edgar Filing: PHARMION CORP - Form 8-K

PHARMION CORP
Form 8-K
May 31, 2007

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) May 31, 2007

Pharmion Corporation

(Exact name of registrant as specified in its charter)

Delaware	000-50447	84-1521333
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
2525 28th Street, Boulder, Colorado		80301
(Address of principal executive offices)		(Zip Code)
Registrant's telephone number, including area code		720-564-9100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: PHARMION CORP - Form 8-K

Item 8.01

Other Events.

On May 31, 2007, Pharmion Corporation (the "Company") announced that data from 18 abstracts of studies investigating the Company's marketed and pipeline products will be presented or published at the American Society of Clinical Oncology's 43rd Annual Meeting in Chicago (June 1-5, 2007).

The press release is filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference in its entirety.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release issued by Pharmion Corporation on May 31, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMION CORPORATION

Date: May 31, 2007

By: /s/ Steven N. Dupont

Name: Steven N. Dupont

Title: Vice President and General Counsel